TrialsgrambetaRCTs are beautiful

COMBINE

2006

Combined Pharmacotherapies and Behavioural Interventions

In 1,383 adults with alcohol dependence, medical management plus naltrexone or combined behavioural intervention reduced heavy-drinking days relative to placebo or acamprosate, with no additive effect.

Result

Primary endpoint: Percent days abstinent and time to heavy-drinking relapse

Naltrexone (HR 0.72) and CBI each effective with medical management; acamprosate no effect; no additive benefit.

Original publication
Subtopic
Alcohol
Design
9-arm RCT, USA
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Anton RF, et al. JAMA. 2006;295(17):2003-2017.doi 10.1001/jama.295.17.2003

Discussion & critique

Established a flexible pharma + behavioural toolkit; the long-debated acamprosate signal failed in this US sample.